Tag Archives: Biotech

COVID-19 fax maker CureVac nearly triples Nasdaq debut

Shares of German biotechnology company CureVac nearly third in their Nasdaq debut Friday, marking the first stock market debut of a company developing a potential vaccine to combat the new coronavirus. The stock opened at $ 44 per share, up from the initial public offering price of $ 16 per …

Read More »